GSE112401
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor and estrogen receptor signalling pathways in endocrine resistant breast cancer
Our data supports the potential combination of inhibition of ERBB2/3 signalling with mTORC1 perturbation and endocrine therapy in patients who have relapsed on endocrine therapy and retain a functional ER. Overall design: RNAseq examination of gene expression changes in MCF72a-LTED tumour xenografts due to treatment with RAD001 (RAD), the pan-ERBB inhibitor neratinib (Ner) and fulvestrant ICI182780 (Ful)